You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for New Drug Application (NDA): 204516


✉ Email this page to a colleague

« Back to Dashboard


NDA 204516 describes BRISDELLE, which is a drug marketed by Sebela Ireland Ltd and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the BRISDELLE profile page.

The generic ingredient in BRISDELLE is paroxetine mesylate. There are thirty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
Summary for 204516
Tradename:BRISDELLE
Applicant:Sebela Ireland Ltd
Ingredient:paroxetine mesylate
Patents:4
Suppliers and Packaging for NDA: 204516
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516 NDA AUTHORIZED GENERIC Padagis US LLC 0574-0279 0574-0279-30 30 CAPSULE in 1 BOTTLE (0574-0279-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 7.5MG BASE
Approval Date:Jun 28, 2013TE:ABRLD:Yes
Patent:⤷  Sign UpPatent Expiration:May 4, 2025Product Flag?Substance Flag?YDelist Request?
Patent:⤷  Sign UpPatent Expiration:Apr 6, 2029Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Patent:⤷  Sign UpPatent Expiration:Aug 4, 2026Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

Expired US Patents for NDA 204516

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.